FDA has approved EPKINLY for the treatment of adults with relapsed/refractory follicular lymphoma – Genmab

Genmab shared a post on LinkedIn:

“Breaking News:

The FDA has approved our medicine for the treatment of adults with relapsed/refractory follicular lymphoma who have received at least two prior therapies.

This approval marks the second FDA-approved indication for our therapy, developed in collaboration with AbbVie.”

Source: Genmab/LinkedIn